Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis

(2021) Ivane Gamkrelidze et al.   LIVER INTERNATIONAL

An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy

(2019) Guglielmo Borgia et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study

(2018) Jia-Horng Kao et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4

(2018) Gamal Esmat et al.   JOURNAL OF HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2018

(2018) Jean-Michel Pawlotsky et al.   JOURNAL OF HEPATOLOGY

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

(2017) Karine Lacombe et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)

(2017) Malte H. Wehmeyer et al.   JOURNAL OF MEDICAL VIROLOGY

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

(2017) Christophe Hézode et al.   LIVER INTERNATIONAL

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study

(2017) Olav Dalgard et al.   PLoS One

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

(2015) David R. Nelson et al.   HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disparity in market prices for hepatitis C virus direct-acting drugs

(2015) Isabelle Andrieux-Meyer et al.   Lancet Global Health